{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:05:25Z","timestamp":1790240725378,"version":"4.1.0"},"reference-count":75,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,2,9]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Inhibition of SPHK1 in human AML cells induces MCL1 degradation and caspase-dependent cell death. SPHK1 inhibitors reduce leukemic burden and prolong survival in orthotopic patient-derived xenografts of AML.<\/jats:p>","DOI":"10.1182\/blood-2016-06-720433","type":"journal-article","created":{"date-parts":[[2016,12,12]],"date-time":"2016-12-12T21:50:37Z","timestamp":1481579437000},"page":"771-782","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":83,"title":["Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia"],"prefix":"10.1182","volume":"129","author":[{"given":"Jason A.","family":"Powell","sequence":"first","affiliation":[{"name":"Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Zhu","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Toubia","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa R.","family":"Pitman","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig T.","family":"Wallington-Beddoe","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A. B.","family":"Moretti","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Iarossi","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya E.","family":"Samaraweera","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik","family":"Cummings","sequence":"additional","affiliation":[{"name":"Department of Haematology, Alfred Hospital and Monash University, Australian Centre for Blood Diseases, Melbourne, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley S.","family":"Ramshaw","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Thomas","sequence":"additional","affiliation":[{"name":"Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford University, Stanford, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Haematology, Alfred Hospital and Monash University, Australian Centre for Blood Diseases, Melbourne, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel F.","family":"Lopez","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"D\u2019Andrea","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9527-2740","authenticated-orcid":false,"given":"Stuart M.","family":"Pitson","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, SA, Australia;"},{"name":"School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9550","key":"2019111905243058400_B1","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet"},{"issue":"1","key":"2019111905243058400_B2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2015-07-604538","article-title":"Emerging therapeutic drugs for AML","volume":"127","author":"Stein","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111905243058400_B3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.tibs.2010.08.001","article-title":"Regulation of sphingosine kinase and sphingolipid signaling","volume":"36","author":"Pitson","year":"2011","journal-title":"Trends Biochem Sci"},{"key":"2019111905243058400_B4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-4419-6741-1_10","article-title":"Extracellular and intracellular actions of sphingosine-1-phosphate","volume":"688","author":"Strub","year":"2010","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"2019111905243058400_B5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2174\/156800910791208599","article-title":"Inhibitors of the sphingosine kinase pathway as potential therapeutics","volume":"10","author":"Pitman","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"issue":"17","key":"2019111905243058400_B6","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1158\/0008-5472.CAN-09-0664","article-title":"Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts","volume":"69","author":"Kapitonov","year":"2009","journal-title":"Cancer Res"},{"issue":"8","key":"2019111905243058400_B7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/emmm.201200244","article-title":"Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1\/sphingosine 1-phosphate signalling to regulate tumour metastasis","volume":"4","author":"Ponnusamy","year":"2012","journal-title":"EMBO Mol Med"},{"issue":"2","key":"2019111905243058400_B8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1096\/fj.08-117572","article-title":"Role for sphingosine kinase 1 in colon carcinogenesis","volume":"23","author":"Kawamori","year":"2009","journal-title":"FASEB J"},{"issue":"19","key":"2019111905243058400_B9","doi-asserted-by":"crossref","first-page":"7211","DOI":"10.1128\/MCB.02341-05","article-title":"Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation","volume":"26","author":"Kohno","year":"2006","journal-title":"Mol Cell Biol"},{"key":"2019111905243058400_B10","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1038\/ctg.2013.21","article-title":"Sphingosine kinase 1 promotes malignant progression in colon cancer and independently predicts survival of patients with colon cancer by competing risk approach in South Asian population","volume":"5","author":"Tan","year":"2014","journal-title":"Clin Transl Gastroenterol"},{"issue":"15","key":"2019111905243058400_B11","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.18632\/oncotarget.1874","article-title":"SPHK1 regulates proliferation and survival responses in triple-negative breast cancer","volume":"5","author":"Datta","year":"2014","journal-title":"Oncotarget"},{"issue":"3","key":"2019111905243058400_B12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1940-6207.CAPR-10-0299","article-title":"A role of sphingosine kinase 1 in head and neck carcinogenesis","volume":"4","author":"Shirai","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"2","key":"2019111905243058400_B13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/hed.21418","article-title":"Increased radiation sensitivity of head and neck squamous cell carcinoma with sphingosine kinase 1 inhibition","volume":"33","author":"Sinha","year":"2011","journal-title":"Head Neck"},{"issue":"18","key":"2019111905243058400_B14","first-page":"5962","article-title":"Discovery and evaluation of inhibitors of human sphingosine kinase","volume":"63","author":"French","year":"2003","journal-title":"Cancer Res"},{"issue":"9","key":"2019111905243058400_B15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2174\/187152011797655078","article-title":"Regulation of sphingosine kinase in hematological malignancies and other cancers","volume":"11","author":"Pitson","year":"2011","journal-title":"Anticancer Agents Med Chem"},{"issue":"3","key":"2019111905243058400_B16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12185-008-0052-0","article-title":"Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells","volume":"87","author":"Sobue","year":"2008","journal-title":"Int J Hematol"},{"issue":"3","key":"2019111905243058400_B17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1365-2141.2008.07474.x","article-title":"In vitro anti-leukaemia activity of sphingosine kinase inhibitor","volume":"144","author":"Ricci","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111905243058400_B18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.leu.2404023","article-title":"Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1","volume":"20","author":"Bonhoure","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"2019111905243058400_B19","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1124\/jpet.114.219659","article-title":"The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines","volume":"352","author":"Dick","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"2019111905243058400_B20","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2008-02-138958","article-title":"A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia","volume":"112","author":"Paugh","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111905243058400_B21","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.bbrc.2015.03.114","article-title":"SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo","volume":"460","author":"Yang","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"D1","key":"2019111905243058400_B22","doi-asserted-by":"crossref","first-page":"D917","DOI":"10.1093\/nar\/gkv1101","article-title":"BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis","volume":"44","author":"Bagger","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2019111905243058400_B23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1074\/mcp.M113.035600","article-title":"Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics","volume":"13","author":"Fagerberg","year":"2014","journal-title":"Mol Cell Proteomics"},{"issue":"3","key":"2019111905243058400_B24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/sj.emboj.7600948","article-title":"Growth factor pleiotropy is controlled by a receptor Tyr\/Ser motif that acts as a binary switch","volume":"25","author":"Guthridge","year":"2006","journal-title":"EMBO J"},{"issue":"5","key":"2019111905243058400_B25","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood-2012-08-447441","article-title":"Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription","volume":"122","author":"Thomas","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2019111905243058400_B26","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1182\/blood-2009-02-204818","article-title":"Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML","volume":"114","author":"Powell","year":"2009","journal-title":"Blood"},{"key":"2019111905243058400_B27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-1-61779-800-9_2","article-title":"Isoform-selective assays for sphingosine kinase activity","volume":"874","author":"Pitman","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"2","key":"2019111905243058400_B28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1525-1578(10)60458-8","article-title":"Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay","volume":"5","author":"Murphy","year":"2003","journal-title":"J Mol Diagn"},{"issue":"3","key":"2019111905243058400_B29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2141.2008.07205.x","article-title":"A rapid, one step assay for simultaneous detection of FLT3\/ITD and NPM1 mutations in AML with normal cytogenetics","volume":"142","author":"Huang","year":"2008","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111905243058400_B30","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3324\/haematol.2014.113092","article-title":"Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice","volume":"100","author":"Lee","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"2019111905243058400_B31","doi-asserted-by":"crossref","first-page":"e1001515","DOI":"10.1371\/journal.pbio.1001515","article-title":"Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival","volume":"11","author":"Thomas","year":"2013","journal-title":"PLoS Biol"},{"issue":"11","key":"2019111905243058400_B32","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1182\/blood.V99.11.4100","article-title":"The nonobese diabetic\/severe combined immunodeficient (NOD\/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse","volume":"99","author":"Lock","year":"2002","journal-title":"Blood"},{"issue":"9","key":"2019111905243058400_B33","doi-asserted-by":"crossref","first-page":"7065","DOI":"10.18632\/oncotarget.3178","article-title":"A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties","volume":"6","author":"Pitman","year":"2015","journal-title":"Oncotarget"},{"issue":"20","key":"2019111905243058400_B34","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1093\/emboj\/cdg540","article-title":"Activation of sphingosine kinase 1 by ERK1\/2-mediated phosphorylation","volume":"22","author":"Pitson","year":"2003","journal-title":"EMBO J"},{"issue":"1","key":"2019111905243058400_B35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1084\/jem.20040559","article-title":"Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling","volume":"201","author":"Pitson","year":"2005","journal-title":"J Exp Med"},{"issue":"11","key":"2019111905243058400_B36","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nbt1350","article-title":"Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region","volume":"25","author":"Ishikawa","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2019111905243058400_B37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/asheducation-2014.1.14","article-title":"Treating acute myeloid leukemia in older adults","volume":"2014","author":"Wang","year":"2014","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"2","key":"2019111905243058400_B38","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"2019111905243058400_B39","first-page":"487","article-title":"Effect of more than one inhibitor","author":"Webb","year":"1963"},{"issue":"7","key":"2019111905243058400_B40","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"issue":"2","key":"2019111905243058400_B41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2019111905243058400_B42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/blood-2014-10-604975","article-title":"Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia","volume":"126","author":"Pan","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111905243058400_B43","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1101\/gad.182980.111","article-title":"Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia","volume":"26","author":"Glaser","year":"2012","journal-title":"Genes Dev"},{"issue":"1","key":"2019111905243058400_B44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood-2011-05-357418","article-title":"Sox4 cooperates with CREB in myeloid transformation","volume":"120","author":"Sandoval","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2019111905243058400_B45","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1182\/blood.V99.7.2617","article-title":"Expression of cyclic adenosine monophosphate response-element binding protein in acute leukemia","volume":"99","author":"Crans-Vargas","year":"2002","journal-title":"Blood"},{"issue":"5","key":"2019111905243058400_B46","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"issue":"5","key":"2019111905243058400_B47","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"issue":"2","key":"2019111905243058400_B48","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1158\/0008-5472.CAN-06-3964","article-title":"Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res"},{"issue":"3","key":"2019111905243058400_B49","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V91.3.991","article-title":"Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse","volume":"91","author":"Kaufmann","year":"1998","journal-title":"Blood"},{"issue":"11","key":"2019111905243058400_B50","doi-asserted-by":"crossref","first-page":"9833","DOI":"10.1074\/jbc.M412356200","article-title":"Sphingosine 1-phosphate analogs as receptor antagonists","volume":"280","author":"Davis","year":"2005","journal-title":"J Biol Chem"},{"issue":"46","key":"2019111905243058400_B51","doi-asserted-by":"crossref","first-page":"35957","DOI":"10.1074\/jbc.M110.117945","article-title":"Sphingosine 1-phosphate receptor 4 uses HER2 (ERBB2) to regulate extracellular signal regulated kinase-1\/2 in MDA-MB-453 breast cancer cells","volume":"285","author":"Long","year":"2010","journal-title":"J Biol Chem"},{"issue":"1","key":"2019111905243058400_B52","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0008-6363(03)00260-8","article-title":"Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2","volume":"58","author":"Ohmori","year":"2003","journal-title":"Cardiovasc Res"},{"issue":"12","key":"2019111905243058400_B53","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1016\/j.bmcl.2011.04.097","article-title":"Discovery, design and synthesis of the first reported potent and selective sphingosine-1-phosphate 4 (S1P4) receptor antagonists","volume":"21","author":"Guerrero","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"2019111905243058400_B54","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3390\/jcm4030460","article-title":"Molecular genetic markers in acute myeloid leukemia","volume":"4","author":"Yohe","year":"2015","journal-title":"J Clin Med"},{"issue":"2","key":"2019111905243058400_B55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/MOH.0000000000000123","article-title":"Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L","volume":"22","author":"Stein","year":"2015","journal-title":"Curr Opin Hematol"},{"issue":"9","key":"2019111905243058400_B56","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood-2014-03-560557","article-title":"Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy","volume":"124","author":"D\u00f6hner","year":"2014","journal-title":"Blood"},{"issue":"15, pt 1","key":"2019111905243058400_B57","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1158\/1078-0432.CCR-07-0381","article-title":"Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia","volume":"13","author":"Karp","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2019111905243058400_B58","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.leukres.2009.11.007","article-title":"Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia","volume":"34","author":"Karp","year":"2010","journal-title":"Leuk Res"},{"issue":"11","key":"2019111905243058400_B59","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.2009.25.4888","article-title":"Phase I\/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia","volume":"28","author":"Ravandi","year":"2010","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111905243058400_B60","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"issue":"57","key":"2019111905243058400_B61","doi-asserted-by":"crossref","first-page":"7904","DOI":"10.1038\/sj.onc.1210587","article-title":"Sphingosine kinase-1 mediates BCR\/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells","volume":"26","author":"Li","year":"2007","journal-title":"Oncogene"},{"issue":"24","key":"2019111905243058400_B62","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1111\/febs.12446","article-title":"Sphingosine-1-phosphate receptor 2","volume":"280","author":"Adada","year":"2013","journal-title":"FEBS J"},{"issue":"48","key":"2019111905243058400_B63","doi-asserted-by":"crossref","first-page":"5559","DOI":"10.1038\/onc.2013.502","article-title":"Enhanced expression of transferrin receptor 1 contributes to oncogenic signalling by sphingosine kinase 1","volume":"33","author":"Pham","year":"2014","journal-title":"Oncogene"},{"issue":"22","key":"2019111905243058400_B64","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1182\/blood-2010-08-300772","article-title":"Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A","volume":"117","author":"Salas","year":"2011","journal-title":"Blood"},{"issue":"14","key":"2019111905243058400_B65","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.febslet.2010.05.061","article-title":"Mcl-1; the molecular regulation of protein function","volume":"584","author":"Thomas","year":"2010","journal-title":"FEBS Lett"},{"issue":"32","key":"2019111905243058400_B66","doi-asserted-by":"crossref","first-page":"21950","DOI":"10.1074\/jbc.M114.587873","article-title":"Inhibition of protein phosphatase 2A (PP2A) prevents Mcl-1 protein dephosphorylation at the Thr-163\/Ser-159 phosphodegron, dramatically reducing expression in Mcl-1-amplified lymphoma cells","volume":"289","author":"Nifoussi","year":"2014","journal-title":"J Biol Chem"},{"issue":"7042","key":"2019111905243058400_B67","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"issue":"2","key":"2019111905243058400_B68","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"3","key":"2019111905243058400_B69","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov"},{"issue":"9","key":"2019111905243058400_B70","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-07-1919","article-title":"Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)","volume":"68","author":"Konopleva","year":"2008","journal-title":"Cancer Res"},{"issue":"10","key":"2019111905243058400_B71","doi-asserted-by":"crossref","first-page":"e108694","DOI":"10.1371\/journal.pone.0108694","article-title":"A multicenter phase I\/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia","volume":"9","author":"Schimmer","year":"2014","journal-title":"PLoS One"},{"issue":"24","key":"2019111905243058400_B72","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1158\/1078-0432.CCR-08-0999","article-title":"A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies","volume":"14","author":"Schimmer","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111905243058400_B73","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/sj.leu.2405098","article-title":"Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway","volume":"22","author":"Zhang","year":"2008","journal-title":"Leukemia"},{"issue":"25","key":"2019111905243058400_B74","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1182\/blood-2011-09-378141","article-title":"Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process","volume":"119","author":"Rahmani","year":"2012","journal-title":"Blood"},{"issue":"13","key":"2019111905243058400_B75","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1152\/physiolgenomics.00173.2013","article-title":"Rational combination of dual PI3K\/mTOR blockade and Bcl-2\/-xL inhibition in AML","volume":"46","author":"Vachhani","year":"2014","journal-title":"Physiol Genomics"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/6\/771\/1402131\/blood720433.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/6\/771\/1402131\/blood720433.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T05:25:10Z","timestamp":1574141110000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/6\/771\/36336\/Targeting-sphingosine-kinase-1-induces"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,9]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,2,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-06-720433","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,9]]}}}